QurAlis’ Post

#Characterization of #Adult #Patients with #Pilocytic #Astrocytoma with an Aggressive #Clinical #Course. Retrospective #Cross-Sectional Study. #Single #Center Experience A #researcharticle authored by ✍ Poluektov Yuri #Background: Pilocytic astrocytoma (PA) is a common tumor of the central nervous system and is considered a benign condition. However, in some cases PA can demonstrate aggressive clinical behavior. #Aim: To analyze and correlate factors leading to an aggressive course of disease in patients with PA. #Methods: As part of a retrospective study, medical records of adult patients (over 18 years of age) with a histological diagnosis of pilocytic astrocytoma were examined. #Results: 19 patients with signs of an aggressive course of the disease were identified. It was found that the age of the patients did not differ significantly between the groups... #Conclusion: A small percentage of PA are prone to an aggressive clinical course. One should be more wary of patients with a “benign” diagnosis... To get full-length article kindly go through the link https://lnkd.in/gZndU4zU We do accept #PPTs and #Video Articles to be publish within our Journal. You can send us your article to given email #Email: onlinescientificresearch@gmail.com

In STRIVE, natalizumab treatment demonstrated effectiveness in clinical, magnetic resonance imaging (MRI), and patient-reported outcomes (PROs) in patients with early relapsing-remitting multiple sclerosis (RRMS). This post hoc analysis examined the effectiveness and safety of natalizumab in patients who self-identified as either Black/African American (AA) or Hispanic/Latino. Read more on the research conducted by Northwestern's Dr Roumen Balabanov investigating the impact of a #multiplesclerosis treatment in #AfricanAmerican and #Hispanic / #Latinx patients: https://lnkd.in/g2DhRKZP #Chicago #Chicagoland

New research from the Global #Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN): ✅ Exploring #Craniofacial Features of POLR3-Related Leukodystrophy Listen and read more: https://lnkd.in/e-RU6G-3

A recent study concluded MAP-Bayesian estimation for patient-specific AUC is comparable to NCA and may enhance tacrolimus TDM in stable kidney transplant recipients (KTRs). The study compared tacrolimus AUC determined by Non-Compartmental Analysis (NCA) using intensive sampling to Maximum a Posteriori-Bayesian (MAP-Bayesian) estimates from robust (n = 9 samples/subject) and sparse (n = 2 samples/subject) sampling in 67 stable KTRs and a validation group of similar patients. Read the full study via the National Library of Medicine (NLM) and PubMed: https://bit.ly/47pfynV | #Tacrolimus #Bayesian #PrecisionMedicine #PrecisionDosing

Excellent 5-Year results from WATER II when combined with 5-year results from the original WATER study demonstrate that Aquablation therapy provides long-term symptom relief while preserving sexual function for patients with small and large prostates. 🙏🏻 #bph #bps #prostate #1stchoicetreatment #preserveejaculation #sexualfunction #proceptbiorobotics